Here is the full list of pages on glaucoma.phoolish.org

Here is the full list of pages on glaucoma.phoolish.org



46. Microincisional cataract surgery and Thinoptx rollable intraocular lens implantation
45. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study
44. Therapeutic strategies for normal-tension glaucoma
43. Primary lensectomy following acute primary angle closure glaucoma
42. Otago Glaucoma Surgery Outcome Study: follow-up of young patients who underwent Molteno implant surgery
41. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis
40. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery
39. Long-term clinical results of selective laser trabeculoplasty in the treatment of primary open angle glaucoma
38. Short- and medium-term intraocular pressure lowering effects of combined phacoemulsification and non-penetrating deep sclerectomy without scleral
37. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension
36. Trabeculectomy for the management of uveitic glaucoma
35. Observational survey on the use of dual therapy in ocular hypertension or glaucoma treatment
34. Glaucoma in children: are we making progress?
33. Baerveldt glaucoma implant in paediatric patients
32. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma
31. The effect of aspirin and warfarin therapy in trabeculectomy
30. Long-term results of Molteno implant insertion in cases of neovascular glaucoma
29. Ahmed Glaucoma Valve implantation in African American and white patients
28. Treating ocular hypertension to reduce glaucoma risk : when to treat?
27. Rescula as an alternative therapy for Beta-blockers with long-term drift effect in glaucoma patients
26. Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma
25. Long-term outcome of pediatric aphakic glaucoma
24. Prospective, long-term evaluation of steroid-induced glaucoma
23. Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma
22. IOP-Lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension
21. Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients
20. Long-term results of surgery in childhood glaucoma
19. Long-term follow-up of selective laser trabeculoplasty in primary open-angle glaucoma
18. Efficacy of laser trabeculoplasty in phakic and pseudophakic patients with primary open-angle glaucoma.
17. Dose, timing and frequency of subconjunctival 5-fluorouracil injections after glaucoma filtering surgery
16. Neovascular glaucoma : Aetiology, pathogenesis and treatment
15. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma
14. Intraocular Pressure-Lowering Effect of Adding Dorzolamide or Latanoprost to Timolol A Meta-analysis of Randomized Clinical Trials
13. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and
12. Glaucoma
11. The clinical applications of Fluorouracil in ophthalmic practice
10. Cortisone glaucoma: epidemiological, clinical, and therapeutic study
09. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients w
08. Experience with the polymer-coated hydroxyapatite implant after enucleation in 126 patients
07. Endoscopic laser cyclophotocoagulation in pediatric glaucoma with corneal opacities
06. Endoscopic diode laser cyclophotocoagulation in the management of aphakic and pseudophakic glaucoma in children
05. Glaucoma surgery and retinal pathology
04. Nonpenetrating glaucoma surgery: a critical evaluation
03. What is Glaucoma?
02. Are You at Risk For Glaucoma?
01. A Glaucoma Gene

Microincisional cataract surgery and Thinoptx rollable intraocular lens implantation

Cinhuseyinoglu N, Celik L, Yaman A, Arikan G, Kaynak T, Kaynak S.
Ophthalmology Clinic, SSK Okmeydani Hospital, Istanbul, Turkey.

BACKGROUND: Microincisional cataract surgery is a safe procedure with a very short learning period for an experienced cataract surgeon and rollable ultrathin intraocular lenses eliminate the need for enlargement of corneal incision. The purpose of the study was to evaluate the safety and efficacy of cataract surgery through a corneal microincision and implantation of rollable ultrathin intraocular lenses. The setting was Dokuz Eylul University Medical Faculty, Ophthalmology Department, Izmir, Turkey and SSK Okmeydani Hospital, Ophthalmology Clinic, Istanbul, Turkey. PATIENTS AND METHODS: Ninety eyes in 85 patients were operated on through clear corneal microincisions with sleeveless phacoemulsification and rollable intraocular lenses were implanted. Forty-six of the patients were men and 39 were women between the ages of 27 and 83, with a mean of 51 years. Two eyes had atrophic senile macular degeneration, 4 eyes had nonspecific retinal pigment epithelial changes with chorioretinal atrophy, and 4 patients had diabetes mellitus without retinopathy. Three eyes had posterior capsular opacifications of unknown etiology. Two eyes had primary open angle glaucoma (PAAG) with cup to disc ratios of about 0.5. Three eyes had dense nuclear sclerosis of grade 4 with very low visibility of retinal structures. Other patients had no ocular or systemic pathology other than nuclear/corticonuclear cataract of grade 2-3. Uncorrected and best spectacle-corrected distance and near visual acuities, keratometric values, and refractive status were noted preoperatively and 1 week, 1 month, and 6 months postoperatively. Statistical analysis of keratometric changes between preoperative and postoperative findings was performed using the paired samples t test. RESULTS: At 6 months postoperatively, 1 patient had a best spectacle-corrected visual acuity (BSCVA) of 0.2, the patient with atrophic senile macular degeneration. The rest of the eyes achieved a BSCVA of 0.63 or better. At 6 months postoperatively, 55 (61.11%) eyes had uncorrected visual acuities (UCVA) equal to or better than 0.8 and 83 (92.22%) eyes had BSCVA equal to or better than 0.8 according to the Snellen chart. The mean postoperative corneal astigmatisms at 1 week, 1 month, and 6 months were 0.69+/-0.43 D, 0.66+/-0.46 D and 0.65+/-0.48 D respectively. Statistical analysis revealed a significant change in corneal astigmatisms at the 1st week visit (p<0.05), but not at the 1st and 6th month visits (p>0.05) compared with preoperative findings. CONCLUSION: Based on the limited data in the literature and in this study, it is not possible to make concrete decisions about the benefits and disadvantages of the ThinOptx IOL for longer durations. Intraoperatively, this IOL apparently eliminates the need for enlargement of the corneal incision during implantation. However, the statistical insignificance of induced astigmatisms after microincisions and classical phacoincisions should also be taken into consideration. We conclude that ThinOptx IOL is a pioneering intraocular lens implant that will contribute to the exciting future of cataract refractive surgical procedures. However, both clinical and laboratory investigations are needed to clearly describe the long-term effectiveness of this new rollable IOL.

Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study

Chandrasekaran S, Rochtchina E, Mitchell P.
Centre for Vision Research, Department of Ophthalmology and the Westmead Millennium Institute, the University of Sydney, Australia.

PURPOSE: To examine the relationship between coffee and caffeine intakes and intraocular pressure (IOP). MATERIALS AND METHODS: The Blue Mountains Eye Study examined 3654 participants aged 49+ years in an area west of Sydney, Australia. A detailed medical history questionnaire included average daily intakes of coffee and tea. The eye examination included Goldmann applanation tonometry and automated perimetry. Participants using glaucoma medications or who had previous cataract or glaucoma surgery or signs of pigmentary glaucoma/pigment dispersion, were excluded. Mean and maximum IOP calculations were used. RESULTS: Participants with open-angle glaucoma (OAG) who reported regular coffee drinking had significantly higher mean IOP (19.63 mm Hg) than participants who said that they did not drink coffee (16.84 mm Hg), after multivariate adjustment, P = 0.03. Participants consuming > or = 200 mg caffeine per day had higher mean IOP (19.47 mm Hg) than those consuming < 200 mg caffeine per day (17.11 mm Hg), after adjusting for age, sex, and systolic blood pressure (SBP), P = 0.06. This association did not reach statistical significance after multivariate adjustment. No association between coffee or caffeine consumption and higher IOP was found in participants with ocular hypertension (OH) and those without open-angle glaucoma. CONCLUSIONS: In participants with open-angle glaucoma, this study identified a positive cross-sectional association between coffee consumption/higher caffeine intakes and elevated intraocular pressure.

Therapeutic strategies for normal-tension glaucoma

Orgul S, Zawinka C, Gugleta K, Flammer J.
University Eye Clinic, Basel, Switzerland. sorguel@uhbs.ch

Treatment of normal-tension glaucoma has been a subject of debate for several years. Glaucomatous damage cannot be influenced directly, and current treatment modalities in normal-tension glaucoma are aimed at the control of risk factors. Intraocular pressure is a widely accepted risk factor and its reduction can improve the prognosis in normal-tension glaucoma patients. The repeated demonstration of the importance of hemodynamic factors in normal-tension glaucoma has, however, not been paralleled by a comparable progress in the development of therapeutic modalities capable of influencing favorably ocular blood flow. Today, calcium channel blockers seem to be the most promising adjunctive treatment to be considered in patients with glaucomatous optic neuropathy without increased intraocular pressure. Copyright 2005 S. Karger AG, Basel.

Primary lensectomy following acute primary angle closure glaucoma

Jacobi PC.
Arzte fur Augenheilkunde, VENI VIDI, Koln.

Recent developments and clinical studies indicate that primary phacoemulsification and intraocular lens implantation are safe and effective for the surgical treatment of primary angle closure glaucoma (ACG) compared to conventional iridectomy or laser-iridotomy. When compared to control eyes treated using standard peripheral iridectomy, the outcome in terms of intraocular pressure control, adjunct anti-glaucoma medication, visual acuity, and the necessity for successive surgical interventions favored primary phacoemulsification and intraocular lens implantation. Earlier biometric data underline the importance of the "lens factor" in the pathogenesis of relative pupillary block in ACG obtained by Scheimflug image processing and ultrasound biomicroscopy. Thevast improvements in modern cataract surgery combined with our current understanding of the pathogenesis of relative pupillary block in ACG indicate that lens extraction is a better procedure in uncontrolled angle closure glaucoma than conventional iridectomy.

Otago Glaucoma Surgery Outcome Study: follow-up of young patients who underwent Molteno implant surgery

Ah-Chan JJ, Molteno AC, Bevin TH, Herbison P.
Eye Department, Dunedin Hospital, Dunedin, New Zealand.

OBJECTIVE: To provide data on the results of patients with nonneovascular juvenile glaucoma who had Molteno implant surgery in the province of Otago, New Zealand. DESIGN: Prospective noncomparative case series. PARTICIPANTS: Fifty-five operations in 52 eyes of 45 patients with nonneovascular juvenile glaucoma who had Molteno implant surgery between the ages of 9 and 49 years from 1976 to 2003 at Dunedin Hospital and were observed for a mean of 12.2 years (range, 0.1-25). INTERVENTION: Insertion of a Molteno implant. MAIN OUTCOME MEASURES: Intraocular pressure (IOP) and visual acuity (VA). RESULTS: Insertion of a Molteno implant controlled IOP at < or =21 mmHg with probabilities of 0.89 (95% confidence interval [CI], 0.81-0.97) at both 1 and 2 years and 0.85 (95% CI, 0.75-0.95), 0.78 (95% CI, 0.66-0.90), and 0.71 (95% CI, 0.58-0.85) at 5, 10, and 15 years, respectively. Mean VA was 20/100 preoperatively; improved to 20/60 at 1 year; and stabilized at 20/120 at 5, 10, and 15 years postoperatively. Twenty-nine eyes had their preoperative VA maintained or improved at final follow-up, and the VAs of 17 eyes deteriorated but were at least light perception at final follow-up. CONCLUSION: The use of Molteno implants in cases of nonneovascular juvenile glaucoma controlled IOP with a probability of 0.71 15 years postoperatively, whereas 53% maintained or improved their vision from their preoperative VA at final follow-up.

Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis

Myles ME, Neumann DM, Hill JM.
Department of Ophthalmology, LSU Health Sciences Center, New Orleans, LA, USA.

Age-related macular degeneration, diabetic retinopathy, posterior uveitis, and retinitis due to glaucoma are leading causes of vision loss in the United States and other developed countries. Because these diseases are located in the posterior segment of the eye, topical application of ophthalmic medicines is of limited benefit, since topically applied drugs rarely reach therapeutic levels in the affected posterior tissues such as the choroid and retina. Intravitreal injections can deliver drugs to the posterior segment without the side effects associated with systemic administration. However, the repeated and long-term injections often needed may cause complications, such as vitreous hemorrhage, retinal detachment, or endophthalmitis. Recent advances in ocular drug delivery methods and the development of novel biopharmaceutical agents could lead to new regimens for the treatment of disease of the posterior retina, choroids, and macula. This review will summarize recent literature concerning ocular drug delivery of bioactive compounds to the posterior segment of the eye with emphasis on transscleral iontophoresis.